Ito Shigeki, Sato Tsuyoshi, Maeta Takahiro
Division of Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Cancers (Basel). 2021 Apr 9;13(8):1793. doi: 10.3390/cancers13081793.
The C-X-C chemokine receptor type 4 (CXCR4) is a pleiotropic chemokine receptor that is expressed in not only normal hematopoietic cells but also multiple myeloma cells. Its ligand, stromal cell-derived factor 1α (SDF-1α) is produced in the bone marrow microenvironment. The SDF-1α/CXCR4 axis plays a pivotal role in the major physiological processes associated with tumor proliferation, survival, invasion, dissemination, and drug resistance in myeloma cells. This review summarizes the pleiotropic role of the SDF-1α/CXCR4 axis in multiple myeloma and discusses the future perspective in the SDF-1α/CXCR4 axis-targeted therapies in multiple myeloma.
CXC趋化因子受体4(CXCR4)是一种多效性趋化因子受体,不仅在正常造血细胞中表达,也在多发性骨髓瘤细胞中表达。其配体基质细胞衍生因子1α(SDF-1α)在骨髓微环境中产生。SDF-1α/CXCR4轴在与骨髓瘤细胞的肿瘤增殖、存活、侵袭、播散及耐药相关的主要生理过程中起关键作用。本文综述了SDF-1α/CXCR4轴在多发性骨髓瘤中的多效性作用,并探讨了多发性骨髓瘤中SDF-1α/CXCR4轴靶向治疗的未来前景。